Literature DB >> 24964452

Colonic perforation associated with neostigmine administration.

Christopher R McDonald1, Darren Tonkin2, Peter Hewett2.   

Abstract

Neostigmine is an acetylcholinesterase inhibitor that is increasingly used as a medical treatment in cases of pseudo-obstruction. It has a well-recognized side-effect profile that includes bradycardia and bronchospasm. We present a case of colonic perforation after administration of neostigmine in the treatment of pseudo-obstruction. Published by Oxford University Press and JSCR Publishing Ltd. All rights reserved.
© The Author 2013.

Entities:  

Year:  2013        PMID: 24964452      PMCID: PMC3813601          DOI: 10.1093/jscr/rjt040

Source DB:  PubMed          Journal:  J Surg Case Rep        ISSN: 2042-8812


INTRODUCTION

We report a case of colonic perforation following the administration of neostigmine for the treatment of pseudo-obstruction. Neostigmine is a prokinetic agent that is increasingly being used in the treatment of pseudo-obstruction. There is limited evidence of its efficacy and due to its side-effect profile it should be used with caution.

CASE REPORT

The patient, a 34-year-old female, developed symptoms consistent with pseudo-obstruction on Day 3 post-emergency Caesarean section, which was performed for foetal distress and possible placenta abruption. An abdominal X-ray was performed which showed a significantly dilated colon (Fig. 1), and the diagnosis of pseudo-obstruction was again confirmed on computer tomography (CT) scan of the abdomen which showed a caecum measuring 9.8 cm transversely (Fig. 2). Emergency colonoscopic decompression with the insertion of a flatus tube was performed and medical management, including cessation of opioids, anticholinergics and correction of electrolyte abnormalities, was commenced.
Figure 1:

Plain abdominal X-ray consistent with pseudo-obstruction.

Figure 2:

CT scan of the abdomen showing caecum measuring 9.8 cm transversely.

Plain abdominal X-ray consistent with pseudo-obstruction. CT scan of the abdomen showing caecum measuring 9.8 cm transversely. The patient failed to have a return of normal bowel function post-decompression and after 3 days was administered 500 µg of neostigmine via subcutaneous injection in an attempt to improve bowel motility. That evening she developed fever, and abdominal pain and erect chest X-ray confirmed free gas under her diaphragms (Fig. 3). She was taken to theatre for emergency laparotomy. At operation she was found to have two sites of caecal perforation with a moderate faecal contamination in the right paracolic gutter. A right hemicolectomy with primary anastomosis was performed. She was discharged home on post-operative Day 7 without further complication. It is possible that the serosal tears of the caecum had occurred secondary to either administration of neostigmine or dilatation in the post-Caesarean period.
Figure 3:

Erect chest X-ray confirming perforated visus.

Erect chest X-ray confirming perforated visus.

DISCUSSION

Neostigmine is an agent that inhibits the effects of acetylcholinesterase thereby acting as a prokinetic. The first use of it in the treatment of pseudo-obstruction is attributed to Hutchinson and Griffiths in 1992 [1].Subsequently, there have been several small studies that report it as a safe and effective treatment in pseudo-obstruction [2-4]. It has several well-documented side effects including bradycardia, hypotension, headache, dizziness, muscle cramps, bronchospasm and salivation. There are however only two other reported cases in the literature of colonic perforation in association with the use of neostigmine for the treatment of colonic pseudo-obstruction [5, 6]. Patients with pseudo-obstruction are often unwell with up to 95% of cases associated with significant infection, trauma or recent surgery [7]. Whilst the documented risk of colonic perforation is low, being reported at ∼3%, these patients have a high risk of mortality due to these co-existing factors [8]. The use of neostigmine is not without risk due to its well-documented side-effect profile. Further work is required to examine whether the risk of perforation is increased in patients with pseudo-obstruction who are treated with neostigmine.
  8 in total

1.  Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction.

Authors:  G T Trevisani; N H Hyman; J M Church
Journal:  Dis Colon Rectum       Date:  2000-05       Impact factor: 4.585

2.  Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction.

Authors:  B J Abeyta; R M Albrecht; C R Schermer
Journal:  Am Surg       Date:  2001-03       Impact factor: 0.688

3.  Perforation of the colon after administration of neostigmine.

Authors:  R Mollema; J Jaap Spijkstra; K H Polderman; H P M M Gelissen; A R J Girbes
Journal:  Intensive Care Med       Date:  2004-02-24       Impact factor: 17.440

4.  Colonic perforation following neostigmine administration.

Authors:  David Shi Hao Liu; Srinivasa Yellapu
Journal:  ANZ J Surg       Date:  2012-12       Impact factor: 1.872

Review 5.  Colonoscopy and acute colonic pseudo-obstruction.

Authors:  D K Rex
Journal:  Gastrointest Endosc Clin N Am       Date:  1997-07

6.  Neostigmine for the treatment of acute colonic pseudo-obstruction.

Authors:  R J Ponec; M D Saunders; M B Kimmey
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

7.  Acute colonic pseudo-obstruction: a pharmacological approach.

Authors:  R Hutchinson; C Griffiths
Journal:  Ann R Coll Surg Engl       Date:  1992-09       Impact factor: 1.891

8.  Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases.

Authors:  V W Vanek; M Al-Salti
Journal:  Dis Colon Rectum       Date:  1986-03       Impact factor: 4.585

  8 in total
  1 in total

Review 1.  COVID 19 and the risk of gastro-intestinal perforation: A case series and literature review.

Authors:  Joris Paul Bulte; Nynke Postma; Menno Beukema; Bas Inberg; Abe Gerrit Stegeman; Hans van der Hoeven
Journal:  J Crit Care       Date:  2021-11-02       Impact factor: 3.425

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.